← Leaderboards
Richard C Duke
University Of Colorado Denver
$8,146,162
Attributed
$8,146,162
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2006–23$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,146,162 · 6
By mechanism
U01$5,725,736 · 2
R44$1,995,686 · 2
P30$215,167 · 1
R01$209,573 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- David Charles Irwin$10,493,842
- Firouz Daneshgari$10,050,590
- Heide L Ford$14,422,349
- Carlin S Long$4,194,320
- Sean W Limesand$6,110,588
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsPreventProductionResearch PersonnelMedicalCollaborationsColoradoUniversitiesIntellectual PropertyTechnologyBaseOperationMentorshipDesignNew TechnologyInnovationAreaCommercializationBasic ScienceBusinessesFundingIndustryBiomanufacturingEvaluation Research
Grant awards (12)
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process$1,000,000
R44 · FY2023 · CA · contact PI
Colorado AMC REACH Hub$985,828
U01 · FY2022 · HL · contact PI
Colorado AMC REACH Hub$990,415
U01 · FY2021 · HL · contact PI
Colorado REACH Hub$1,166,125
U01 · FY2020 · HL · contact PI
Colorado AMC REACH Hub$995,236
U01 · FY2020 · HL · contact PI
Colorado AMC REACH Hub$999,434
U01 · FY2019 · HL · contact PI
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics$290,373
U01 · FY2007 · AI · contact PI
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics$298,325
U01 · FY2006 · AI · contact PI
FAS LIGAND AS AN IMMUNOSUPPRESSIVE AGENT$497,843
R44 · FY2001 · AI
FAS LIGAND AS AN IMMUNOSUPPRESSIVE AGENT$497,843
R44 · FY2000 · AI
CORE--IMMUNOLOGY$215,167
P30 · FY2000 · CA
CD95 (FAS) LIGAND AND IMMUNE PRIVILEGED TISSUE$209,573
R01 · FY2000 · AI